|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phar- macological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance:systematic review and meta-analysis显示文摘 | Clare L Gillies Keith R Abrams Paul C Lambert | 2007 | BMJ2007，334，： | 1 |
| 2 | 成人2型糖尿病不同筛查及预防策略成本效益分析显示文摘目的 比较针对2型糖尿病预防及治疗的4种筛查策略及随后予以的干预措施:(a)筛查2型糖尿病患者使其能接受早期检查及治疗,(b)筛查2型糖尿病和糖耐量受损患者,对糖耐量受损的人群予以生活方式干预以延缓或预防糖尿病的发生,(c)同(b)但予以药物干预措施,(d)不筛查。
设计 成本效益决策分析建立在对概率的发展和评估基础上,是从筛查到死亡的综合性经济决策分析模型。
研究对象 一组假设人群,筛查时年龄45岁,高于平均糖尿病风险水平。
数据来源 电子书目数据库收录的已发表的临床试验和流行病学研究;补充数据分别来自英国和威尔士健康统计署、风险筛查(STAR)研究和ADDITION研究的Leicester部分。
方法 建立一种决策树/Markov混合模型,以模拟每一种筛查策略的长期效用,包括临床和成本效益终点。该模型假设水平跨度为50年时间,其成本效益折损率为3.5%。采用敏感度分析以验证模型假设及确定哪种模型数据输入对结果的影响最大。
结果 与不筛查策略比较,筛查2型糖尿病、筛查糖尿病和糖耐量受损并予以生活方式干预、筛查糖尿病和糖耐量受损并予以药物干预治疗3种策略,每获得一个质量调整生命年(QALY)估计所需成本分别为(每年成本效益贴现率为3.5%)14150英镑(17560欧元;27860美元)、6242英镑和7023英镑。在支付意愿阈值为20000英镑时,各主动筛查策略通过干预产生的成本效益概率分别为49%,93%和85%。
结论 对年龄45岁、高于平均风险水平的人群进行2型糖尿病和糖耐量受损的筛查,并对糖耐量受损人群予以适当的干预似乎具有很好的成本效益。单独筛查糖尿病而不对糖耐量受损人群予以干预的策略具有的成本效益仍不确定,需要进一步研究确定早期检测糖尿病的作用。 | Clare L Gillies Paul C Lambert Keith R Abrams Alex J Sutton Nicola J Cooper Ron T Hsu Melanie J Davies Kamlesh Khunti 张晓梅(译) 纪立农(校) | 2008 | 英国医学杂志中文版2008，11，5： | 1 |
| 3 | Project Governance 显示文摘 | Keith Lambert | 2003 | World Project Management Week2003，，6： | 1 |
| 4 | Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo 显示文摘 | Jesse J Smith Renee Deehan Kenney David J Gagne Brian P Frushour William Ladd Heidi L Galonek Kristine Israelian Jeffrey Song Giedre Razvadauskaite Amy V Lynch David P Carney Robin J Johnson Siva Lavu Andre Iffland Peter J Elliott Philip D Lambert Keith O Elliston Michael R Jirousek Jill C Milne and Olivier Boss | 2009 | BMC Systems Biology2009，284，27： | 1 |
| 5 | The Structure of Organizational Incentives显示文摘 | Lambert R Larcker David Weigelt Keith | 1993 | Administrative Science Quarterly1993，38，3： | 1 |
| 6 | Project Governance显示文摘 | Keith Lambert | | World Project Management Week0，2003，： | 1 |
| 7 | Project governance显示文摘 | | 2003 | World ProjectManagement Week2003，，3： | 1 |
| 8 | The Structure of Organizational Incentives 显示文摘 | Lambert R Larcker David Weigelt Keith | 1993 | Administrative Science Quarterly1993，，3： | 1 |
| 9 | Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative显示文摘BACKGROUND Cytoreductive surgery(CRS)with hyperthermic intraperitoneal chemotherapy(HIPEC)for peritoneal carcinomatosis can be performed in two ways:Open or closed abdominal technique.AIM To evaluate the impact of HIPEC method on post-operative and long-term survival outcomes.METHODS Patients undergoing CRS with HIPEC from 2000-2017 were identified in the United States HIPEC collaborative database.Post-operative,recurrence,and overall survival outcomes were compared between those who received open vs closed HIPEC.RESULTS Of the 1812 patients undergoing curative-intent CRS and HIPEC,372(21%)patients underwent open HIPEC and 1440(79%)underwent closed HIPEC.There was no difference in re-operation or severe complications between the two groups.Closed HIPEC had higher rates of 90-d readmission while open HIPEC had a higher rate of 90-d mortalities.On multi-variable analysis,closed HIPEC technique was not a significant predictor for overall survival(hazards ratio:0.75,95%confidence interval:0.51-1.10,P=0.14)or recurrence-free survival(hazards ratio:1.39,95%confidence interval:1.00-1.93,P=0.05)in the entire cohort.These findings remained consistent in the appendiceal and the colorectal subgroups.CONCLUSION In this multi-institutional analysis,the HIPEC method was not independently associated with relevant post-operative or long-term outcomes.HIPEC technique may be left to the discretion of the operating surgeon. | Jennifer L Leiting Jordan M Cloyd Ahmed Ahmed Keith Fournier Andrew J Lee Sophie Dessureault Seth Felder Jula Veerapong Joel M Baumgartner Callisia Clarke Harveshp Mogal Charles A Staley Mohammad Y Zaidi Sameer H Patel Syed A Ahmad Ryan J Hendrix Laura Lambert Daniel E Abbott Courtney Pokrzywa Mustafa Raoof Christopher J LaRocca Fabian M Johnston Jonathan Greer Travis E Grotz | 2020 | World Journal of Gastrointestinal Oncology2020，12，7： | 1 |
| 10 | Project Governance显示文摘 | Keith Lambert | 2003 | World Project Management Week2003，，： | 1 |
| 11 | The ciliary neurotrophic factor and its receptor, CNTFRα显示文摘 | Mark W. Sleeman Keith D. Anderson Philip D. Lambert George D. Yancopoulos Stanley J. Wiegand | 2000 | Pharmacochemistry Library2000，，： | 1 |
| 12 | Project Governance 显示文摘 | Keith Lambert | 2003 | World Project Management Week2003，，： | 1 |
| 13 | Project governance 显示文摘 | KEITH LAMBERT | 2003 | World Project Manage- ment Week2003，，3： | 1 |
| 14 | Project Govemance显示文摘 | Keith Lambert | 2003 | World Project Management Week2003，，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员